- SEK206.18m
- -SEK60.82m
- SEK26.00m
Brief: Orexo Q2 EBITDA Loss Widens To SEK 41.1 Mln
Brief: Orexo Signs Commercial Partnership Agreement With Sober Grid
Brief: Orexo: USPTO Issues Another Two Patents Relating To ZUBSOLV
Brief: Orexo Q1 EBITDA Swings To Loss Of SEK 23.9 Mln
Brief: Orexo Gets U.S. Patent for Zubsolv
Brief: Orexo Publishes Prospectus And Applies For Admission To Trading Of Corporate Bonds
Brief: Orexo Starts Collaboration With ApexB.io And Magellan Rx Management
Brief: Orexo Calls For Redemption Of Outstanding Bonds, Gets Temporary Waiver
Brief: Orexo Says Successfully Issued Senior Unsecured Callable Floating Rate Bonds
Brief: Orexo Contemplates Issue Of Senior Unsecured Callable Floating Rate Bonds
Brief: Orexo Expects FDA Filing Of OX124 Mid 2022
Brief: Orexo Q4 EBITDA Slumps To SEK 1.0 Mln
Brief: Orexo Strengthens IP Rights For Overdose Rescue Drug OX124
Brief: Orexo Announces New Us Patent For Zubsolv
Advisory: Multiple dated alerts withdrawn
Brief: Orexo Signs License And Supply Deal With Accord Healthcare
Brief: Orexo Q3 EBITDA Ex-Items Falls To Sek 50.3 Mln
Brief: Orexo Commences Patent Infringement Litigation Against Sun Pharmaceutical
Brief: Orexo Receives Paragraph IV Notice Letter For In The US